Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	17,258	16,544	15,846	14,925	15,878
Revenue Growth (YoY)	4.32%	4.41%	6.17%	-6.00%	-4.69%
Cost of Revenue	8,320	8,481	8,200	7,952	8,284
Gross Profit	8,938	8,064	7,645	6,973	7,594
Selling, General & Admin	3,973	3,702	3,498	3,445	3,528
Research & Development	1,013	998	953	838	967
Other Operating Expenses	1,794	3,666	2,762	4,887	1,384
Total Operating Expenses	6,780	8,366	7,213	9,170	5,879
Operating Income	2,157	-303	433	-2,197	1,716
Interest Expense	-934	-981	-1,057	-966	-1,058
Other Non-Operating Income (Expense)	-15	-1	-2	-21	-9
Total Non-Operating Income (Expense)	-949	-982	-1,059	-987	-1,067
Pretax Income	1,223	-1,284	-624	-3,163	658
Provision for Income Taxes	-180	676	-7	-643	211
Net Income	1,411	-1,639	-559	-2,446	417
Minority Interest in Earnings	7	-320	-56	-53	39
Net Income to Common	1,411	-1,639	-559	-2,446	417
Shares Outstanding (Basic)	1,145	1,131	1,119	1,110	1,102
Shares Outstanding (Diluted)	1,163	1,131	1,119	1,110	1,107
Shares Change (YoY)	2.83%	1.07%	0.81%	0.27%	1.10%
EPS (Basic)	1.23	-1.45	-0.50	-2.20	0.38
EPS (Diluted)	1.21	-1.45	-0.50	-2.20	0.38
Free Cash Flow	1,148	749	842	1,042	236
Free Cash Flow Growth	53.27%	-11.04%	-19.19%	341.52%	-63.01%
Free Cash Flow Per Share	0.99	0.66	0.75	0.94	0.21
Gross Margin	51.79%	48.74%	48.25%	46.72%	47.83%
Operating Margin	12.50%	-1.83%	2.73%	-14.72%	10.81%
Profit Margin	8.22%	-11.84%	-3.88%	-16.74%	2.87%
FCF Margin	6.65%	4.53%	5.31%	6.98%	1.49%
EBITDA	3,159	756	1,586	-889	3,046
EBITDA Margin	18.30%	4.57%	10.01%	-5.96%	19.18%
EBIT	2,157	-303	433	-2,197	1,716
EBIT Margin	12.50%	-1.83%	2.73%	-14.72%	10.81%
Effective Tax Rate	-14.72%	-52.65%	1.12%	20.33%	32.07%

Updated Jan 28, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q